Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Estimating the Need for Complex Malignant Hematologists in Ontario Using Monte Carlo Simulation

Jonathan Wang, MASc, Andre C. Schuh, MD FRCPC, Deanna Wu, MBA, Christopher N. Bredeson, MD MSc, FRCPC, Jacinta Meharchand, MD FRCPC, Lisa Favell, MBA, Louis Fu, MISt, Kelly J. Woltman, MA, C. Tom Kouroukis, MDMSc,FRCPC

Blood (2017) 130 (Supplement 1): 3397.

https://doi.org/10.1182/blood.V130.Suppl_1.3397.3397

Published: 2017

Journal Articles

Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome

Blood (2017) 130 (Supplement 1): 2596.

https://doi.org/10.1182/blood.V130.Suppl_1.2596.2596

Published: 2017

Journal Articles

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy

Blood (2016) 128 (22): 4263.

https://doi.org/10.1182/blood.V128.22.4263.4263

Published: 2016

Journal Articles

Outcomes of Adult Philadelphia Positive Acute Lymphoblastic Leukemia Patients Treated with Pediatric Multi-Agent Chemotherapy and Imatinib and the Impact of Residual Disease Monitoring on Survival

Solaf Sami Kanfar, MD, Steven M. Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Aaron D. Schimmer, MD PhD, Andre C. Schuh, MD FRCPC, Hassan Sibai, MD, Karen W.L. Yee, MD, Mark D. Minden, MD PhD

Blood (2016) 128 (22): 3976.

https://doi.org/10.1182/blood.V128.22.3976.3976

Published: 2016

Journal Articles

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Justyna Bartoszko, MD, Tony Panzarella, BSc MSc, Caroline Jane McNamara, MBBS, Anthea Lau, Aaron D. Schimmer, MD PhD, Andre C. Schuh, MD FRCPC, Hassan Sibai, MD, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Rebecca Devlin, PhD, Vikas Gupta, MD

Blood (2016) 128 (22): 4264.

https://doi.org/10.1182/blood.V128.22.4264.4264

Published: 2016

Journal Articles

A Retrospective Study of Venous Thromboembolism in Acute Leukemia Patients during Prolonged Hospital Stay. the Princess Margaret Cancer Centre Experience

Hassan Sibai, MD, Umberto Falcone, MD PhD, Arjun Datt Law, MBBS,MDDM, Ali Hosni, MD, Carmen Tan, Naoko Sakurai, Phm, MSc, Andre C. Schuh, MD FRCPC, Mark D. Minden, MD PhD, Steven M. Chan, MD PhD, Karen W.L. Yee, MD, Vikas Gupta, MD FRCP, FRCPath, Aaron D. Schimmer, MD PhD, Jack T Seki, PharmD

Blood (2016) 128 (22): 2615.

https://doi.org/10.1182/blood.V128.22.2615.2615

Published: 2016

Journal Articles

Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations

Arjun Datt Law, MBBS, MDDM, Mahadeo A. Sukhai, BSc, MSc, PhD, Mariam Thomas, PhD, Andrea Arruda, MSc., Narmin Ibrahimova, Steven M. Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Hassan Sibai, MD, Karen W.L. Yee, MD, Dwayne L. Barber, PhD, Tracy L. Stockley, PhD, Suzanne Kamel-Reid, PhD DABMG, FACMG, Andre C. Schuh, MD FRCPC

Blood (2016) 128 (22): 2886.

https://doi.org/10.1182/blood.V128.22.2886.2886

Published: 2016

Journal Articles

Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived

Sara Farshchi Zarabi, MD, Steven M. Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dina Khalaf, BSc, MSc, MD, Andrzej Lutynski, MD, Mark D. Minden, MD PhD, Amr Rostom, MD, Anna Rydlewski, MD, Andre C. Schuh, MD FRCPC, Hassan Sibai, MD, Karen W.L. Yee, MD, Aaron D. Schimmer, MD PhD

Blood (2016) 128 (22): 2800.

https://doi.org/10.1182/blood.V128.22.2800.2800

Published: 2016

Journal Articles

Anticoagulation Prophylaxis in Asparaginase-Based Therapy in Adults with Acute Lymphoblastic Leukemia

Hassan Sibai, MD, Umberto Falcone, MD PhD, Arjun Datt Law, MBBS,MDDM, Naoko Sakurai, Phm, MSc, Lalit Saini, MD, Tian Q Wang, Andrew Stessman, Joseph Samuel, Eshetu G. Atenafu, Ali Hosni, MD, Andre C. Schuh, MD FRCPC, Karen W.L. Yee, MD, Vikas Gupta, MD FRCP, FRCPath, Mark D. Minden, MD PhD, Steven M. Chan, MD PhD, Aaron D. Schimmer, MD PhD, Joseph M. Brandwein, MD FRCPC, Jack T Seki, PharmD

Blood (2016) 128 (22): 1453.

https://doi.org/10.1182/blood.V128.22.1453.1453

Published: 2016

Journal Articles

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Max S Topp, MD, Zachary Zimmerman, MD PhD, Paul Cannell, MD, Hervé Dombret, MD PhD, Johan Maertens, MD PhD, Andre C. Schuh, MD FRCPC, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong

Blood (2016) 128 (22): 222.

https://doi.org/10.1182/blood.V128.22.222.222

Published: 2016

Journal Articles

Aplastic Anemia in Pregnancy - a Single Centre, North American Case Series

Kelly E McGowan, MD FRCPC, Ann Kinga Malinowski, MD MSc, FRCSC, Andre C. Schuh, MD FRCPC, Nadine Shehata, MD MSC

Blood (2016) 128 (22): 3909.

https://doi.org/10.1182/blood.V128.22.3909.3909

Published: 2016

Journal Articles

Outcomes of Mixed Phenotype Leukemia, Not Otherwise Specified (NOS), in Adults: A Single Centre Retrospective Review from 2000 to 2014

Sita D. Bhella, MD, Rumina Musani, MDFCAP, FRCPC, Anna Porwit, MDPhD, Anne Tierens, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Aaron D. Schimmer, MD PhD, Andre C Schuh, MD FRCPC, Karen W.L. Yee, MD, Mark D. Minden, MD PhD

Blood (2015) 126 (23): 4865.

https://doi.org/10.1182/blood.V126.23.4865.4865

Published: 2015

Journal Articles

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Andre C Schuh, MD FRCPC, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Mohamed Shanavas, MD FRACP, FRCPA, Andrzej Lutynski, MD, Amr Rostom, MD, Anna Rydlewski, MD, Dina Khalaf, BSc, MSc, MD, Karen W.L. Yee, MD

Blood (2015) 126 (23): 4893.

https://doi.org/10.1182/blood.V126.23.4893.4893

Published: 2015

Journal Articles

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Joseph Brandwein, MD FRCPC, Vikas Gupta, MD FRCP, FRCPath, Johann Hitzler, MD FRCP (C), FAAP, Dina Khalaf, BSc, MSc, MD, Andrzej Lutynski, MD, Aaron D. Schimmer, MD PhD, Andre C Schuh, MD FRCPC, Amr Rostom, MD, Anna Rydlewski, MD, Karen W.L. Yee, MD, Mark D. Minden, MD PhD

Blood (2015) 126 (23): 3717.

https://doi.org/10.1182/blood.V126.23.3717.3717

Published: 2015

Journal Articles

Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care

Blood (2015) 126 (23): 3848.

https://doi.org/10.1182/blood.V126.23.3848.3848

Published: 2015

Journal Articles

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

Blood (2014) 124 (21): 621.

https://doi.org/10.1182/blood.V124.21.621.621

Published: 2014

Journal Articles

Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis

Uday Deotare, MD DM, Marwan Shaheen, MD, Joseph M. Brandwein, MD FRCPC, Bethany Gill, BSc, MMath, Suzanne Kamel-Reid, PhD DABMG, FACMG, Karen W.L. Yee, MDFRCPC, Anna Rydlewski, MD, Andrzej Lutynski, MD, Amr Rostom, MDCFPC, Aaron D Schimmer, MDPhD, Mark D. Minden, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MRCP, FRCPC, MPH, Naheed Alam, MBBS,MD, Andre C Schuh, MD FRCPC

Blood (2014) 124 (21): 3693.

https://doi.org/10.1182/blood.V124.21.3693.3693

Published: 2014

Journal Articles

Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Justyna Bartoszko, Tony Panzerella, Anthea Lau, Naheed Alam, MBBS,MD, Aaron D Schimmer, MDPhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Andre C Schuh, MD FRCPC, Mohamed Shanavas, MD FRACP, FRCPA, Karen W.L. Yee, MDFRCPC, Vikas Gupta, MD FRCP, FRCPath

Blood (2014) 124 (21): 3180.

https://doi.org/10.1182/blood.V124.21.3180.3180

Published: 2014

Journal Articles

FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., Andre C Schuh, MD FRCPC, Mark D Minden, MDPhD, Aaron D Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MRCP, FRCPC, MPH, Naheed Alam, MBBS, MD, Andrzej Lutynski, MD, Amr Rostom, MD CFPC, Anna Rydlewski, MD, Karen Yee, MD

Blood (2014) 124 (21): 5285.

https://doi.org/10.1182/blood.V124.21.5285.5285

Published: 2014

Journal Articles

A Standard, 3-Tube, 10-Color Flow Cytometry Panel for Acute Myeloid Leukemia Diagnosis Can be Used for MRD Detection at Day 30 after Induction, and Is Predictive of Early Relapse

Naheed Alam, MBBS,MD, Anne Tierens, MD PhD, Karen Yee, MD, Aaron D. Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Mark D. Minden, MD PhD, Matthew Seftel, MRCP, FRCPC, MPH, Anna Porwit, MDPhD, Andre C Schuh, MD FRCPC

Blood (2014) 124 (21): 5336.

https://doi.org/10.1182/blood.V124.21.5336.5336

Published: 2014

NARROW

Estimating the Need for Complex Malignant Hematologists in Ontario Using Monte Carlo Simulation

Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy

Outcomes of Adult Philadelphia Positive Acute Lymphoblastic Leukemia Patients Treated with Pediatric Multi-Agent Chemotherapy and Imatinib and the Impact of Residual Disease Monitoring on Survival

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

A Retrospective Study of Venous Thromboembolism in Acute Leukemia Patients during Prolonged Hospital Stay. the Princess Margaret Cancer Centre Experience

Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations

Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived

Anticoagulation Prophylaxis in Asparaginase-Based Therapy in Adults with Acute Lymphoblastic Leukemia

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Aplastic Anemia in Pregnancy - a Single Centre, North American Case Series

Outcomes of Mixed Phenotype Leukemia, Not Otherwise Specified (NOS), in Adults: A Single Centre Retrospective Review from 2000 to 2014

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis

Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Standard, 3-Tube, 10-Color Flow Cytometry Panel for Acute Myeloid Leukemia Diagnosis Can be Used for MRD Detection at Day 30 after Induction, and Is Predictive of Early Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only